Can-Fite BioPharma Ltd. — 2020 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter filing; the supplied text does not provide standalone Q4 results. Financial figures below are in U.S. dollars unless noted otherwise.
Business context
Can-Fite is an Israeli clinical-stage biopharmaceutical company developing oral small-molecule candidates targeting the A3 adenosine receptor. Its lead programs are Piclidenoson (psoriasis and COVID-19), Namodenoson (liver cancer and NASH), and CF602 (erectile dysfunction). The company had no approved products or product-sales revenue; revenue came from licensing and distribution arrangements.
Financial results and liquidity
| Metric | 2020 | 2019 | Change / context |
|---|---|---|---|
| Revenue | $0.763 million | $2.032 million | Down 63%; primarily lower recognition of licensing advances. No product-sales revenue. |
| Research and development expense | $11.951 million | $10.976 million | Up 8.9%; principally clinical development costs. |
| General and administrative expense | $2.951 million | $3.063 million | Down 3.6%. |
| Operating loss | $14.139 million | $12.007 million | Loss widened as expenses substantially exceeded licensing revenue. |
| Net loss | $14.443 million | $12.625 million | Loss widened; 2020 also included a $0.715 million deemed dividend related to warrant exercises, presented below net loss. |
| Net cash used in operating activities | $12.063 million | $11.084 million | Cash burn increased. |
| Net cash provided by financing activities | $17.683 million | $10.167 million | Primarily equity and warrant-related financings. |
At year-end, cash and cash equivalents were $8.268 million, versus $2.697 million a year earlier; current assets were $9.400 million and current liabilities $1.269 million. Total assets were $9.523 million, total liabilities $3.449 million, and shareholders’ equity $6.074 million. Liabilities included deferred revenue and operating lease obligations; the filing says it does not anticipate significant long-term borrowings. Cash increased by $5.571 million during the year, despite operating cash burn, as financing proceeds offset outflows.
Management said available resources were expected to fund operations for at least 12 months from the report’s issuance, while also stating that substantial additional financing would be needed for longer-term development. The independent auditor identified liquidity and capital resources as a critical audit matter because of the judgment involved in assessing that runway.
Material developments and outlook
- Piclidenoson: The Phase III COMFORT psoriasis study continued after an interim review recommended dropping one dose group; management expected enrollment completion in the second half of 2021. Development for rheumatoid arthritis was discontinued after the Phase III ACROBAT study missed its primary endpoint of non-inferiority to methotrexate. A COVID-19 Phase II study was ongoing; first-patient enrollment was announced in March 2021, after year-end.
- Namodenoson: The Phase II HCC study missed its primary endpoint in the full population, though management reported favorable survival results in the CPB7 subgroup. Management planned a Phase III HCC study and a Phase IIb NASH study, both expected to begin in Q4 2021. The company also reported positive Phase II NASH results, including improvements in selected liver measures at the 25 mg dose; these are clinical findings, not evidence of approval or commercial benefit.
- Other programs and partnerships: CF602 remained preclinical. The Univo cannabis collaboration expired at year-end 2020. In March 2021, after the reporting period, Can-Fite signed an Ewopharma distribution agreement that included $2.25 million upfront, potential milestones of up to $40.45 million, and royalties; these are subsequent events, not 2020 revenue.
- Outlook: Management expected R&D spending to increase through 2021 and beyond and G&A expense to remain broadly stable through 2021. Future funding was expected from existing cash, licensing milestones, collaborations, and additional equity or debt financing. Milestone receipts are contingent, and the company cautioned that financing may not be available on acceptable terms.
Risks, contingencies, and unusual items
- The company has incurred losses since inception, had an accumulated deficit of $125.469 million at year-end, and depends on external capital and licensing income. Equity financings and warrants create substantial dilution risk: year-end ordinary shares outstanding rose to 463.769 million from 120.653 million at the end of 2019.
- Clinical outcomes remain uncertain. Several prior Piclidenoson studies and the Namodenoson HCC study did not meet primary endpoints; earlier-stage or subgroup results may not predict pivotal-trial outcomes.
- COVID-19 could disrupt trials, recruitment, suppliers, regulatory processes, and access to capital. Competition, regulatory approval, manufacturing, commercialization partners, and reimbursement also present material risks.
- Intellectual-property exposure includes the expiration of key A3AR proliferative-disease patents during 2020 (apart from a U.S. patent expected to expire in 2021), and the company no longer has the expired NIH composition-of-matter license for Piclidenoson. It relies on other patents, licenses, and potential regulatory exclusivity.
- The company reported no material litigation and no material off-balance-sheet arrangements. Contractual obligations disclosed at year-end totaled approximately $0.193 million, excluding potential future Leiden University milestones.
- Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2020. The auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Whether cash runway remains adequate after the stated clinical-trial commitments and subsequent-period spending, and what financing is required beyond the management’s 12-month estimate.
- Fully diluted share count, outstanding warrants and options, exercise prices, and the dilution implications of future capital raises.
- Current status, enrollment, and endpoint performance of the COMFORT psoriasis, Namodenoson HCC and NASH, and Piclidenoson COVID-19 trials.
- Whether projected licensing milestones are achievable and whether the March 2021 Ewopharma upfront payment and other subsequent events are reflected in later-period financial statements.
- The filing contains inconsistent accounting-basis statements: introductory text says IFRS, while the auditor’s opinion and financial-statement notes say U.S. GAAP. Confirm the applicable basis against the audited statements and SEC filing.